FINWIRES · TerminalLIVE
FINWIRES

Sonic Healthcare's Fiscal 2026 EBITDA Forecast to Be AU$1.9 Billion, Jefferies Says

By

Sonic Healthcare (ASX:SHL) continues to expect earnings before interest, taxes, depreciation, and amortization (EBITDA) for fiscal year 2026 in the range of AU$1.87 billion to AU$1.95 billion at constant currency, compared with Jefferies' forecast of AU$1.9 billion, according to a Thursday note from Jefferies.

Sonic completed its previously flagged sale and leaseback of its Brisbane Hub Laboratory, and further property sale and leaseback transactions are under consideration.

The purchase price was AU$445 million, with rent, under a triple net lease arrangement, to begin at AU$25 million per annum. Sonic expects to book a fiscal year 2026 gain on sale before tax of around AU$100 million.

The investment firm retained its hold rating on Sonic and raised the price target to AU$22.60 per share from AU$22.55 per share.

Related Articles

Asia

Market Chatter: U.S. Government Holds Off on Adding Chinese Firms, Including DeepSeek, to Trade Blacklist

The U.S. government has held off on adding more than 100 Chinese companies, including artificial intelligence startup DeepSeek and memory chipmaker CXMT, on a trade blacklist to avoid raising tensions with Beijing, Reuters reported Wednesday.The firms were flagged for inclusion to the Commerce Department's Entity List due to national security risks.According to Reuters, the U.S. government believes DeepSeek supported China's military and intelligence operations and tried to illegally access advanced U.S. chips through Southeast Asian shell companies.CXMT was similarly designated as a Chinese military company by the Biden administration but is yet to be added to the list, the report said.DeepSeek and CXMT did not immediately respond to requests for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Shanghai Composite^SZSE
Asia

Zydus Lifesciences Completes Acquisition of US-Based Assertio Holdings

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), through its wholly-owned subsidiary, Zara Merger Sub, has completed the acquisition of all outstanding shares of common stock of NASDAQ-listed Assertio Holdings, according to a Tuesday filing to the Indian stock exchanges.The purchase was done at $23.50 per share of common stock of the U.S.-based specialty oncology pharmaceutical company Assertio, as part of a merger deal amounting to a total consideration of $166.3 million on a fully diluted basis.After the completion of the merger, Assertio will be the surviving entity, in which all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share.Assertio will become a wholly-owned subsidiary of the company, and its common stock will no longer be listed or traded on the Nasdaq, the statement said.

BOM:532321NSE:ZYDUSLIFE
Asia

Mapletree Pan Asia Commercial Trust Prices SG$200 Million Offering of Green Bonds

Mapletree Pan Asia Commercial Trust (SGX:N2IU) priced SG$200 million worth of 2.530% fixed-rate senior green bonds due in 2033, according to a Tuesday filing with the Singapore Exchange.Shares of the trust were up nearly 2% in Wednesday's trading.The debt securities will be issued on June 25. Deal proceeds used to finance or refinance eligible green projects.OCBC and United Overseas Bank are the joint lead managers and joint bookrunners.

SGX:N2IU